Louise Chen
Stock Analyst at Scotiabank
(2.40)
# 2,439
Out of 4,876 analysts
301
Total ratings
42.16%
Success rate
-0.46%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $17.23 | +364.31% | 3 | Jun 6, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Sector Perform | $135 | $128.15 | +5.35% | 2 | Jun 2, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.56 | +476.92% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $13.06 | +7.20% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.99 | +503.02% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.36 | +170.14% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $49.55 | +11.00% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.62 | +314.36% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $20.62 | +142.48% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $3.69 | +307.06% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $7.34 | +131.77% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $29.83 | +134.66% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $10.05 | +397.51% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $18.08 | +65.93% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $36.19 | +51.98% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.90 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $67.70 | +136.34% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.88 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.24 | +85.64% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $152.01 | +41.44% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.28 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $78.83 | +96.63% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.60 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $795.12 | +11.30% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.31 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.39 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.75 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.38 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $48.03 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $186.79 | +7.07% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.88 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.56 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.90 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.45 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $521.00 | +77.54% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.74 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $2.59 | +2,409.65% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.97 | +415.20% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $2.02 | +1,137.62% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.34 | +225.95% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.40 | +247.22% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.17 | +327.35% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.62 | +455.56% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.71 | +62,269,272.69% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $437.03 | -40.97% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.56 | -9.42% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $2.16 | +2,214.81% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.32 | +1,415.15% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.00 | +542.86% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $17.23
Upside: +364.31%
Blueprint Medicines
Jun 2, 2025
Downgrades: Sector Perform
Price Target: $135
Current: $128.15
Upside: +5.35%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.56
Upside: +476.92%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $13.06
Upside: +7.20%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.99
Upside: +503.02%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.36
Upside: +170.14%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $49.55
Upside: +11.00%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.62
Upside: +314.36%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $20.62
Upside: +142.48%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.69
Upside: +307.06%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $7.34
Upside: +131.77%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $29.83
Upside: +134.66%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $10.05
Upside: +397.51%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $18.08
Upside: +65.93%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $36.19
Upside: +51.98%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.90
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $67.70
Upside: +136.34%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.88
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.24
Upside: +85.64%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $152.01
Upside: +41.44%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.28
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $78.83
Upside: +96.63%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.60
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $795.12
Upside: +11.30%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.31
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.39
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.75
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.38
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $48.03
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $186.79
Upside: +7.07%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.88
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.56
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.90
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $521.00
Upside: +77.54%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.74
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $2.59
Upside: +2,409.65%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.97
Upside: +415.20%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $2.02
Upside: +1,137.62%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.34
Upside: +225.95%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.40
Upside: +247.22%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.17
Upside: +327.35%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.62
Upside: +455.56%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.71
Upside: +62,269,272.69%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $437.03
Upside: -40.97%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.56
Upside: -9.42%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $2.16
Upside: +2,214.81%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.32
Upside: +1,415.15%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.00
Upside: +542.86%